3 recruiting, 3 terminated, 2 active not recruiting, 2 completed. 10 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Recruiting 3, Terminated 3, Active not recruiting 2, Completed 2 |
| Phase 2 | 3 | Terminated 2, Recruiting 1 |
Follow Carcinosarcoma: new trials by email Literature Review of Carcinosarcoma trials Research Report on Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PHST001 in Advanced Solid Tumors PHST001, Paclitaxel, Topotecan - Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Recruiting | Pheast Therapeutics | 426 | 2025-03-31 | 2026-10-05 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer Atezolizumab, ONC201 - Endometrial Cancer, Metastasis | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 58 | 2023-10-23 | 2026-01-29 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2023-09-14 | 2026-10-09 |
| (VELA) Study of BLU-222 in Advanced Solid Tumors BLU-222, Carboplatin, Ribociclib - Advanced Solid Tumors, HR+ Breast Cancer | Phase 1 | Terminated | Blueprint Medicines Corporation | 50 | 2022-04-07 | 2025-11-28 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-11-12 |
| A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors Rebastinib, Paclitaxel - Locally Advanced or Metastatic Solid Tumor | Phase 1 / Phase 2 | Terminated | Deciphera Pharmaceuticals, LLC | 177 | 2018-10-25 | 2024-12-27 |
| Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Galunisertib, Paclitaxel, Carboplatin - Carcinosarcoma, Ovarian | Phase 1 | Completed | University of Oklahoma | 26 | 2017-08-23 | 2024-08-07 |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors belinostat, 5-Fluorouracil (5-FU) - Tumor | Phase 1 | Completed | Valerio Therapeutics | 35 | 2005-09-01 | 2015-07-08 |
Endometrial Neoplasms (7) · Ovarian Neoplasms (5) · Breast Neoplasms (4) · Neoplasm Metastasis (4) · Fallopian Tube Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Stomach Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Adenocarcinoma, Mucinous (1) · Adenosarcoma (1) · Carcinoma, Bronchogenic (1)
Neoplasms by Histologic Type (10) · Neoplasms, Complex and Mixed (10) · Neoplasms, Connective and Soft Tissue (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases (9) · Genital Diseases, Female (9) · Genital Neoplasms, Female (9) · Neoplasms (9) · Neoplasms by Site (9) · Sarcoma (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Uterine Diseases (8) · Uterine Neoplasms (7)
Biopsy (3) · Magnetic Resonance Spectroscopy (3) · Paclitaxel (3) · Specimen Handling (3) · Carboplatin (2) · Fluorouracil (2) · trastuzumab deruxtecan (2) · Axitinib (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · DCC-2036 (1) · Doxorubicin (1) · Folfox protocol (1) · Fulvestrant (1) · Gemcitabine (1)
National Cancer Institute (NCI) (2) · Blueprint Medicines Corporation (1) · Deciphera Pharmaceuticals, LLC (1) · Incyte Corporation (1) · Mayo Clinic (1) · Pheast Therapeutics (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Oklahoma (1) · Valerio Therapeutics (1)
United States (9) · United Kingdom (2) · Italy (1)
Joyce F Liu (1) · Kanwal P Raghav (1) · Kathleen Moore, MD (1) · Philomena Colucci (1) · Victoria Bae-Jump, MD, PhD (1) · Yanyan Lou, MD, PhD (1)
2023 (1), R21CA267584 (1), UM1CA186688 (1), UM1CA186709 (1)